MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

MDT

96.46

-0.47%↓

A

146.44

-1.03%↓

VEEV

228.35

-1.98%↓

HQY

84.03

-0.27%↓

PHR.US

16.54

-3.44%↓

Search

Smith & Nephew PLC ADR

Gesloten

31.87 -5.09

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

31.83

Max

33.58

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

29.768

87.826

Dividendrendement

2.29

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Neutraal

12 Maanden Prognose

+6.15% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

2.29%

2.26%

Marktinformatie

By TradingEconomics

Marktkapitalisatie

14B

Vorige openingsprijs

36.96

Vorige sluitingsprijs

31.87

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Smith & Nephew PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

12 jan 2026, 23:54 UTC

Marktinformatie

CBA Could Underperform Again in 2026 -- Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 23:48 UTC

Marktinformatie

Nikkei May Rise on Weaker Yen -- Market Talk

12 jan 2026, 23:43 UTC

Marktinformatie

Gold Edges Lower on Likely Technical Correction -- Market Talk

12 jan 2026, 23:18 UTC

Acquisities, Fusies, Overnames

Paramount Sues Warner Bros., Plans Proxy Fight. The Ellisons Aren't Giving Up. -- Barrons.com

12 jan 2026, 21:56 UTC

Marktinformatie

Light & Wonder Gets Positive Outcome From Lawsuit -- Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

12 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 21:18 UTC

Marktinformatie

Pfizer CEO Sees Large Cash Market for Obesity Drugs -- Market Talk

12 jan 2026, 20:54 UTC

Winsten

Gap, Fortinet, and More Stocks That Usually Outperform After Earnings -- Barrons.com

12 jan 2026, 20:48 UTC

Marktinformatie

Oil Futures Settle Higher in Choppy Trade -- Market Talk

12 jan 2026, 20:33 UTC

Marktinformatie

U.S. Natural Gas Jumps on Colder Weather Outlook -- Market Talk

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole Sees Banco BPM Stake Helping 2025 Net by EUR200M >ACA.FR

12 jan 2026, 20:18 UTC

Acquisities, Fusies, Overnames

Credit Agricole: European Central Bank Approves Crossing of 20% Threshold in Share Capital of Banco BPM

12 jan 2026, 19:39 UTC

Marktinformatie

J&J CEO: Trump Pact Allows Company to Focus on Core Operations -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Gold and Silver Set New Records on Fed Probe -- Market Talk

12 jan 2026, 19:36 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

12 jan 2026, 19:33 UTC

Marktinformatie

Venezuela's 'Proven' Oil Reserves Raises Questions -- Market Talk

12 jan 2026, 19:24 UTC

Acquisities, Fusies, Overnames

Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23

12 jan 2026, 19:22 UTC

Acquisities, Fusies, Overnames

Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'

12 jan 2026, 18:21 UTC

Acquisities, Fusies, Overnames

Paramount Plans Proxy Fight to Push Hostile Warner Bid -- 2nd Update

12 jan 2026, 18:20 UTC

Acquisities, Fusies, Overnames

This French Biotech Stock Surged 1,700% in 2025. Eli Lilly Is Taking an Interest. -- Barrons.com

12 jan 2026, 18:19 UTC

Marktinformatie

Modest Canadian Economic Impact Seen from Venezuela Changes -- Market Talk

12 jan 2026, 18:16 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Comcast Could Unlock Value With a Spinoff of NBCUniversal Assets, Analysts Say -- Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Global Equities Roundup: Market Talk

12 jan 2026, 18:09 UTC

Marktinformatie

Baidu's Outlook Bodes Well For Shares -- Market Talk

12 jan 2026, 18:01 UTC

Acquisities, Fusies, Overnames

QXO Is Raising Another $1.8 Billion for Its M&A War Chest -- Barrons.com

12 jan 2026, 18:00 UTC

Marktinformatie

Canada's 'Breakeven' Employment Recalibrating -- Market Talk

Peer Vergelijking

Prijswijziging

Smith & Nephew PLC ADR Prognose

Koersdoel

By TipRanks

6.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 35.75 USD  6.15%

Hoogste 37.5 USD

Laagste 34 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

2 ratings

0

Buy

2

Hold

0

Sell

Technische score

By Trading Central

26.64 / 28.37Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bullish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC ADR

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat